93. 原発性胆汁性胆管炎 Primary biliary cholangitis Clinical trials / Disease details


臨床試験数 : 298 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-002698-39-PL
(EUCTR)
03/03/201608/01/2016A Study Evaluating the Effects of Two Doses of MBX-8025 Compared to a Placebo in Patients with Primary Biliary Cirrhosis (PBC) who have not responded to previous treatment with ursodeoxycholic acid (UDCA).A 12-week, double-blind, randomized, placebo-controlled, Phase 2 study to evaluate the effects of two doses of MBX-8025 in subjects with Primary Biliary Cirrhosis (PBC) and an inadequate response to ursodeoxycholic acid (UDCA). Primary Biliary Cirrhosis
MedDRA version: 18.1;Level: LLT;Classification code 10036680;Term: Primary biliary cirrhosis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: MBX-8025
Product Code: MBX-8025
Other descriptive name: MBX-8025
Product Name: MBX 8025
Product Code: MBX 8025
Other descriptive name: MBX-8025
CymaBay Therapeutics Inc.NULLNot RecruitingFemale: yes
Male: yes
75Phase 2United States;Canada;Poland;Germany;United Kingdom
2EUCTR2015-002698-39-DE
(EUCTR)
18/12/201530/09/2015A Study Evaluating the Effects of Two Doses of MBX-8025 Compared to a Placebo in Patients with Primary Biliary Cirrhosis (PBC) who have not responded to previous treatment with ursodeoxycholic acid (UDCA).A 12-week, double-blind, randomized, placebo-controlled, Phase 2 study to evaluate the effects of two doses of MBX-8025 in subjects with Primary Biliary Cirrhosis (PBC) and an inadequate response to ursodeoxycholic acid (UDCA). Primary Biliary Cirrhosis
MedDRA version: 19.1;Level: LLT;Classification code 10036680;Term: Primary biliary cirrhosis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: MBX-8025
Product Code: MBX-8025
INN or Proposed INN: NA
Other descriptive name: MBX-8025
Product Name: MBX 8025
Product Code: MBX 8025
INN or Proposed INN: NA
Other descriptive name: MBX-8025
CymaBay Therapeutics Inc.NULLNot RecruitingFemale: yes
Male: yes
75Phase 2United States;Canada;Poland;Germany;United Kingdom
3EUCTR2015-002698-39-GB
(EUCTR)
11/11/201517/09/2015A Study Evaluating the Effects of Two Doses of MBX-8025 Compared to a Placebo in Patients with Primary Biliary Cirrhosis (PBC) who have not responded to previous treatment with ursodeoxycholic acid (UDCA).A 12-week, double-blind, randomized, placebo-controlled, Phase 2 study to evaluate the effects of two doses of MBX-8025 in subjects with Primary Biliary Cirrhosis (PBC) and an inadequate response to ursodeoxycholic acid (UDCA). Primary Biliary Cirrhosis
MedDRA version: 18.1;Level: LLT;Classification code 10036680;Term: Primary biliary cirrhosis;System Organ Class: 100000004871;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: MBX-8025
Product Code: MBX-8025
Other descriptive name: MBX-8025
Product Name: MBX 8025
Product Code: MBX 8025
Other descriptive name: MBX-8025
CymaBay Therapeutics Inc.NULLNot RecruitingFemale: yes
Male: yes
75Phase 2United States;Canada;Poland;Germany;United Kingdom